Drug design platform combining de novo AI design and large-scale human-relevant testing to make drug development a true engineering discipline.
Nabla Bio is a Cambridge, MA-based biotech that integrates AI-driven generative drug design with human-relevant wet and dry lab validation systems into a single owned platform. The platform designs medicines with actionable properties including binding affinity, developability, cellular function, and in vivo performance, targeting pharma partners seeking to reduce trial-and-error in drug discovery. Nabla partners with leading pharmaceutical companies to advance new medicines to patients. Nabla Bio is a product of Nabla Bio.